Protagonist Therapeutics, Inc. Stock

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq 15:59:51 2024-05-29 EDT 5-day change 1st Jan Change
27.86 USD -7.05% Intraday chart for Protagonist Therapeutics, Inc. -12.13% +21.52%
Sales 2024 * 270M 370M Sales 2025 * 120M 164M Capitalization 1.63B 2.24B
Net income 2024 * 77M 106M Net income 2025 * 2M 2.74M EV / Sales 2024 * 4.42 x
Net cash position 2024 * 442M 605M Net cash position 2025 * 677M 928M EV / Sales 2025 * 7.99 x
P/E ratio 2024 *
24.2 x
P/E ratio 2025 *
-28.3 x
Employees 124
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.96%
More Fundamentals * Assessed data
Dynamic Chart
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing MT
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data CI
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda CI
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study MT
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis CI
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing MT
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing MT
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda DJ
Transcript : Protagonist Therapeutics, Inc. - Special Call
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset CI
More news

Latest transcript on Protagonist Therapeutics, Inc.

1 day-7.05%
1 week-12.13%
Current month+10.97%
1 month+9.02%
3 months-8.28%
6 months+57.52%
Current year+21.52%
More quotes
1 week
27.85
Extreme 27.85
31.22
1 month
24.78
Extreme 24.78
32.64
Current year
21.43
Extreme 21.43
33.34
1 year
13.72
Extreme 13.72
33.34
3 years
6.91
Extreme 6.91
50.54
5 years
4.47
Extreme 4.47
50.54
10 years
4.47
Extreme 4.47
50.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 08-11-30
Director of Finance/CFO 50 22-04-17
Chief Tech/Sci/R&D Officer - 17-06-30
Members of the board TitleAgeSince
Director/Board Member 74 17-06-07
Chairman 69 09-01-31
Director/Board Member 61 23-10-25
More insiders
Date Price Change Volume
24-05-29 27.87 -7.04% 690,925
24-05-28 29.98 -1.41% 434,107
24-05-24 30.41 -0.43% 355,501
24-05-23 30.54 -3.69% 651,987
24-05-22 31.71 0.00% 571,832

Delayed Quote Nasdaq, May 29, 2024 at 03:59 pm

More quotes
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
27.87 USD
Average target price
43.5 USD
Spread / Average Target
+56.08%
Consensus